

STUDY (click for full study details) BRIEF STUDY DESCRIPTION	BRIEF PARTICIPANT CRITERIA
Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Health Participants and Participants with CF <i>New mRNA Therapy for CF</i>	<ul style="list-style-type: none"> ● 18-60 years old ● FEV1 50%-100% ● Not genetically eligible for or not taking modulators (exclusions apply)
Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of CF <i>New inhaled CFTR (HSV-1)-derived vector for CF</i>	<ul style="list-style-type: none"> ● ≥18 years old ● FEV1 50%-100% ● Not genetically eligible for modulators
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG) <i>One IV Antibiotic v. Two IV Antibiotics for treatment of Pulmonary Exacerbation with Pseudomonas</i>	<ul style="list-style-type: none"> ● ≥6 years old ● Needing treatment for a CF pulmonary exacerbation with IV antibiotics
Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators (REACH) <i>Observational Study For People With CF Not Taking Modulators</i>	<ul style="list-style-type: none"> ● ≥18 years old ● Not currently taking modulators
Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With CF Who Are Homozygous for F508del Mutation <i>New Add-On Therapy for People with CF Taking Trikafta®</i>	<ul style="list-style-type: none"> ● ≥18 years old ● F508del homozygous ● FEV1 40%-100% ● Currently taking Trikafta
Phase III. Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY® Study) <i>New Medicine for both CF and Non-CF Bronchiectasis</i>	<ul style="list-style-type: none"> ● ≥18 years old ● Confirmed bronchiectasis ● At least one pulmonary exacerbations requiring antibiotics in last 12 months
Phase 1. Study of VX-828 in Healthy Subjects and in Subjects With CF <i>New Modulator for CF</i>	<ul style="list-style-type: none"> ● ≥18 years old ● Heterozygous F508del with second variant non-responsive to Trikafta ● FEV1 ≥40%